 |
|
 |
|
| |
The Ubiquitin-Proteasome Pathway:
Targets for Disease Treatment and New Tools for Discovery
Event Date: May 1, 2008 12:00 Noon EDT; 9:00 a.m. PDT; 4 p.m. GMT
Brought to you by the Science/AAAS Business Office
|
|
Best viewed on Internet Explorer 6 or better.
|
| |
Real Player |
| For best results when using Real Media, first upgrade to RealPlayer v11. |
| | Real Media Video (56k/150k) | | |
Windows Media Player | | | Windows Media Video (56k/150k) |
|
| |
|
|
| |
Protein modification by ubiquitin or the ubiquitin-like proteins has been implicated in a variety of cellular processes including proteosomal degradation, cell signaling, gene transcription, DNA repair, and protein localization. The nature, location, and extent of these post translational modifications appear to influence their cellular fate. Recent evidence that small molecule inhibitors of the proteasome can be used in the treatment of human cancers has launched intensive efforts to discover new drugs that will selectively inhibit the activities of disease-specific components of the ubiquitin pathway. It has also stimulated the development of new tools to help to better understand the complex mechanisms surrounding ubiquitin.
You will meet with a panel of experts to:
- Learn more about the role of ubiquitin in cellular processes.
- Find out the latest about efforts to find new drugs that target the ubiquitin pathway.
- Hear about the successful application of protein microarray technology for discovering new substrates for ubiquitin ligases.
- Have your questions answered by the experts live and in real-time.
|
|
| |
Speakers:
 |
Alfred Goldberg, Ph.D.
Department of Cell Biology
Harvard Medical School
Boston, MA
Dr. Goldberg received his A.B. degree in biochemistry and his Ph.D. in physiology in 1968 from Harvard University, after attending Harvard Medical School and Cambridge University as a Churchill Scholar. He has been on the faculty of Harvard Medical School for nearly his entire academic career and since 1993 has held the position of Professor of Cell Biology at that institution. His important discoveries have concerned the biochemical mechanisms and physiological regulation of protein breakdown in cells, and the importance of this process in human disease. His laboratory first demonstrated the nonlysosomal ATP-dependent pathway for protein breakdown, now termed the ubiquitin-proteasome pathway. Also of wide impact have been Dr. Goldberg’s studies showing that activation of the ubiquitin-proteasome pathway is critical in muscle atrophy in many disease states. He and his colleagues also first introduced proteasome inhibitors now widely used as research tools.This work led to the development of the proteasome inhibitor, Velcade, now widely used in the treatment of multiple myeloma. Dr. Goldberg’s accomplishments have been recognized with many awards and he has served on the scientific advisory boards of and been a consultant to a number of pharmaceutical and biotechnology companies. He is a Fellow of the American Academy of Arts & Sciences and is among the most cited authors in the life sciences.
|
 |
Gregory Korbel, Ph.D. [Dr Korbel replaces our original speaker, Dr Barry Schweitzer from Invitrogen, who unfortunately could not be with us]
Invitrogen
Branford, CT
Dr Korbel completed his PhD in Organic Chemistry under Matthew Shair in the Department of Chemistry and Chemical Biology at Harvard University. His postdoctoral training was carried out at Harvard Medical School and the Whitehead Institute for Biomedical Research at MIT, and focused on deubiquitinating enzymes and pathways for ubiquitin-mediated and non-ubiquitin-mediated degradation of misfolded proteins in the endoplasmic reticulum. He also trained at Yale School of Medicine, characterizing the role of SUMO and SUMO proteases in cellular senescence. Dr Korbel joined Invitrogen in June 2007 and is currently Senior Scientist and head of Protoarray Services. |
 |
Paul Andrews, Ph.D.
Amgen
Cambridge, MA
Paul Andrews received his Ph.D. in the lab of Dr Yue Xiong at the University of North Carolina at Chapel Hill where he studied the substrate targeting mechanisms of the RING finger and cullin-based family of E3 ubiquitin ligases. He is currently a scientist within the Lead Discovery organization at Amgen, Inc. where he has expanded his exploration of the ubiquitin proteasome pathway.
|
|
|
| |
Moderator: Sean Sanders, Ph.D., Commercial Editor, Science/AAAS
 |
Sean Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. under Sir Dillwyn Williams at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor in 2004 before recently taking the position of Commercial Editor at Science/AAAS.
|
|
|
|
| |
___________________________________________________________________________________________________
|
 |
|
| |
Test Your System
|
| | Help |
| |
Download Real Player
|
| |
Download Windows Media Player
|
|
|